(Reuters) - The prescribing label for Biogen Inc's big-selling oral multiple sclerosis drug Tecfidera has been updated to include a warning of potential liver injury that could require hospitalization, the company said on Wednesday. (Source: Reuters: Health)


Read full article on medworm.com